(Q53241078)

English

Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity.

scientific article published on 12 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

author name string

Dai Mizuno

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Takashi Kimoto

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Tsunetomo Takei

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Akiho Fukuta

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Wakako Shinahara

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Etsuhisa Takahashi

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Mihiro Yano

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Hiroshi Kido

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

language of work or name

0 references

publication date

12 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

29

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

33

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

5368-5378

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Prevention and early treatment of influenza in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Effectiveness of influenza vaccine in health care professionals: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Trivalent intranasal influenza vaccine, live

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Intracellular and intraalveolar localization of surfactant protein A (SP-A) in the parenchymal region of the human lung

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Macrophage and type II cell catabolism of SP-A and saturated phosphatidylcholine in mouse lungs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Metabolism and turnover of lung surfactant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Lung surfactants. I. Comparison of surfactants prepared from lungs of calf, ox, dog and rabbit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

GM-CSF regulates protein and lipid catabolism by alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant. Characterization and biophysical activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Isolation and characterization of mouse nasal-associated lymphoid tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

A method for preparing 2- to 50-micron-thick fresh-frozen sections of large samples and undecalcified hard tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Chlorzoxazone: a probe drug whose metabolism can be used to monitor toluene exposure in rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Mucus clearance as a primary innate defense mechanism for mammalian airways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Innate immunity in the mucosal immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Distinct effects of SP-B and SP-C on the uptake of surfactant-like liposomes by alveolar cells in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Surface modified liposomes for nasal delivery of DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Co-delivery of IL-2 or liposomes augment the responses of mice to a DNA vaccine for pseudorabies virus IE180.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.090

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.05.090

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21669246

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53241078&oldid=1382137301"